Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02222402
Other study ID # NIHR HTA Project Ref 12/23/09
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2015
Est. completion date December 2019

Study information

Verified date February 2020
Source King's College Hospital NHS Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The PEDAL study aims to evaluate the effectiveness of a 9-month intradialytic exercise training intervention designed to improve quality of life (QOL) and alleviate functional limitations in patients with stage 5 Chronic Kidney Disease (CKD) who are on haemodialysis. Exercise rehabilitation will be compared against established treatment options available within UK NHS haemodialysis (HD) units. A qualitative substudy will also investigate the experience and acceptability of the intervention for both participants and members of the renal care team. In addition, we want to examine whether this type of additional exercise treatment is cost effective within the health service setting.

PEDAL is designed as a multi centre randomised clinical trial (RCT) and will recruit 380 adult patients who have been on HD for at least 3 months, from 10 HD sites located in Scotland, England and Wales. The type of exercise programming will consist of cycling exercise performed during each dialysis session plus a muscle conditioning programme performed twice per week. All exercise sessions will be supervised by a physiotherapy assistant. The exercise prescription will be individualised for all patients on the basis of their fitness and clinical status.

The main objective is to examine the impact of exercise rehabilitation on quality of life and well being of patients. We hypothesise that the exercise training delivered during haemodialysis treatment will significantly improve the functional limitations/abilities of the patients leading to the detection of clinically beneficial improvement in quality of life outcome, as measured by the KDQOL-36 physical composite score (PCS) at the primary end point.


Recruitment information / eligibility

Status Completed
Enrollment 335
Est. completion date December 2019
Est. primary completion date December 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria:

1. Prevalent Stage 5 CKD patients (GFR <15 mL/min) receiving maintenance haemodialysis therapy for more than 3 months

2. Male or female

3. Aged >18 years

4. Able to provide written informed consent

Exclusion Criteria:

1. Patients unlikely to be on HD for > 6 months - (this includes cachectic patients, those with severe heart failure, patients in whom dialysis withdrawal is being considered, and patients likely to receive a live-donor transplant or transfer to PD in that period of time);

2. Less than 3 months after the initiation of haemodialysis (patients in this time-frame are generally less clinically stable, many having vascular access procedures performed, and rates of inter-current events, including death and hospitalisation, are very much higher in the first 3 months after commencement of chronic haemodialysis);

3. Deemed to be clinically unstable by treating physician;

4. Dementia or severe cognitive impairment (as will be unable to give consent and/or complete questionnaire assessments);

5. Severe psychiatric disorders - except treated stable

Study Design


Intervention

Behavioral:
INTRA-DIALYTIC EXERCISE TRAINING


Locations

Country Name City State
United Kingdom Kings College Hospital London

Sponsors (2)

Lead Sponsor Collaborator
King's College Hospital NHS Trust National Institute for Health Research, United Kingdom

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from basline in quality of life on the Kidney Disease QOL questionnaire Physical Composite Score (KDQOL-PCS) at month 6. The KDQOL is a disease-specific quality of life measure. Baseline, 6 months
See also
  Status Clinical Trial Phase
Completed NCT02235571 - iChoose Decision Kidney Aid for End-Stage Renal Disease Patients N/A
Active, not recruiting NCT05027074 - Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007) Phase 2
Completed NCT03582592 - Fluid Distribution Timetable on Adherence to Fluid Restriction of Patients With End-Stage Renal Disease on Hemodialysis N/A
Completed NCT02694068 - Biological Determinants of Peritoneal Dialysis
Not yet recruiting NCT02832505 - Applications of MRI in Kidney Disease
Not yet recruiting NCT02590081 - Effect of Sodium Rinsing Fluid on Blood Pressure and Interdialytic Weight Change in Hemodialysis Patients Phase 4
Completed NCT01859884 - Optimizing Kidney Transplant Informed Consent N/A
Completed NCT00509236 - Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1) Phase 3
Completed NCT02009514 - Glucose Containing and Glucose Free Hemodialysate in Type 2 Diabetic Patients Phase 4
Not yet recruiting NCT06377293 - Effect of Dialysis-specific Therapeutic Diet on Biochemical Parameters in Dialysis Patients N/A
Completed NCT01528800 - Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients Phase 2
Completed NCT01863914 - Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula Phase 2
Withdrawn NCT06030050 - Animal Assisted Intervention for Hemodialysis Outpatients N/A
Completed NCT04610593 - Effects of a Mindfulness-based Intervention in Stress, Pain and Quality of Life in People Undergoing Hemodialysis N/A
Recruiting NCT05931276 - CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes Phase 3
Completed NCT00143741 - Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers Phase 1
Active, not recruiting NCT02755610 - Check List to Improve Patient Self-care and Product Defect Report in Continuous Ambulatory Peritoneal Dialysis N/A
Recruiting NCT03142529 - Traditional Chinese Medicine (TCM) Colon Dialysis Treats Non-dialysis End-Stage Kidney Disease Phase 1/Phase 2
Completed NCT02342119 - Increasing Equity in Transplant Evaluation and Living Donor Kidney Transplantation N/A
Recruiting NCT05614115 - Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD Phase 1